reata pharmaceuticals stock forecast
Reata Pharmaceuticals Stock Prediction. Reata Pharmaceuticals Inc.
These Analysts Just Made A Neat Downgrade To Their Reata Pharmaceuticals Inc Nasdaq Reta Eps Forecasts
About the Reata Pharmaceuticals Inc.
. Reata Pharmaceuticals RETA is yet to generate product revenues due to the lack of marketed drugs in its portfolio. Guggenheim assumed coverage on shares of Reata Pharmaceuticals NASDAQRETA Get Rating in a report issued on Wednesday Marketbeat reports. Reata Pharmaceuticals Stock Prediction.
Reata Pharmaceuticals stock monthly and. Technical analysis historical chart. Target levels support and resistance levels.
RETA now What analysts predict. Reata Pharmaceuticals Inc. Reata Pharmaceuticals stock forecast for 2025 by month.
RETA Stock Price Prediction 5125 10459 Upside Based on 6 Wall Street analysts offering 12 month price targets for Reata Pharmaceuticals in the last 3 months. Forecast and historical charts. RETA share price prediction for 2022 2023 2024 2025 2026 and 2027.
Reata Pharmaceuticals Incs market cap currently stands at around 110 billion with investors looking forward to this quarters earnings report slated for Nov 07 2022 Nov. The average price target. Reata Pharmaceuticals RETA stock.
The company has a market. However two of its pipeline candidates are close to potential FDA. What is RETAs Earnings Per Share EPS forecast.
Reata Pharmaceuticals Stock Prediction. Reata Pharmaceuticals has a 12 month low of 1847 and a 12 month high of 11480. RETA one year forecast.
The average Reata Pharmaceuticals stock price prediction forecasts a potential upside of 6898 from the current RETA share price of 2594. Reata Pharmaceuticals Stock Prediction. The share price of Reata Pharmaceuticals Inc.
Reata Pharmaceuticals stock price forecast. Short-term and long-term forecasts for Reata Pharmaceuticals shares. RETA Reata the Company or we a clinical-stage biopharmaceutical company today announced that abstracts highlighting clinical.
1148 1847 50200 Day Moving Average. Negative dynamics for Reata Pharmaceuticals shares will prevail with. NASDAQRETAs beta value is holding at 107 while the average true range ATR indicator is currently reading 217.
RETA shares soared 206 in the last trading session to close at 3021. 2488 2882 This. The move was backed by solid volume with far more shares changing.
NASDAQ RETA opened at 3466 on Wednesday. Forecast target price for 09-30-2022. Target prices for 2022 2023 2024.
Reata Pharmaceuticals Stock Forecast Over the next 52 weeks Reata Pharmaceuticals has on average historically risen by 457 based on the past 5 years of stock performance. Reata Pharmaceuticals Stock Forecast 09-30-2022. 1 day agoReata Pharmaceuticals Inc.
Reata Pharmaceuticals Inc. As of 2022 October 09 Sunday current price of RETA stock is 23780 and our data indicates that the asset price has.
Reta Stock Forecast Price News Reata Pharmaceuticals
Reta Share Price And News Reata Pharmaceuticals Inc Nasdaq
Reata Pharmaceuticals Earnings Preview Reata Pharmaceuticals Nasdaq Reta Benzinga
Reata Pharmaceuticals Inc Reta Stock Price Us75615p1030 Marketscreener
Reta Reata Pharmaceuticals Inc Cl A Stock Overview U S Nasdaq Barron S
Is Reata Pharmaceuticals Inc Reta Stock At The Top Of The Biotechnology Industry
What Is The Current Price Target And Forecast For Reata Pharmaceuticals Reta
List Of Leading Biotech Stocks To Buy In 2021
Reata Deadline Alert Bragar Eagel Squire P C Reminds Investors That A Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals Inc And Encourages Investors To Contact The Firm Business Wire
Reata Pharmaceuticals Inc Reta Stock Price News Info The Motley Fool
Reta Reata Pharmaceuticals Stock Reta Stockholders Class Action Reata Pharmaceuticals Alert Youtube
Reata Pharmaceuticals Inc Reta Stock Price Quote News Stock Analysis
Reata Pharmaceuticals Reta Historical Forecast Data Trefis Trefis
Reata Pharmaceuticals Inc Reta Stock 10 Year History
Reta Def14a 20210610 Htm
Reata Pharmaceuticals Can Rally Nasdaq Reta Seeking Alpha
Trial Triumphs Takeover Talk Boost Reata Pharmaceuticals Warren Huff President And Ceo Discusses Bardoxolone Omaveloxolone And A Possible Expansion Of The Cns Pipeline With Gen Edge Gen Edge Vol 2 No 1
Reata Pharmaceuticals Nasdaq Reta Is In A Good Position To Deliver On Growth Plans
Irving Biotech Reata Pharmaceuticals Sets Terms For Initial Public Offering Dallas Business Journal